Welcome to our dedicated page for Aptargroup news (Ticker: ATR), a resource for investors and traders seeking the latest updates and insights on Aptargroup stock.
AptarGroup, Inc. (NYSE: ATR) generates news across drug delivery, digital health and consumer dispensing technologies. As a global company serving pharmaceutical, beauty, food, beverage, personal care and home care markets, its announcements often highlight new delivery systems, clinical collaborations, acquisitions and financial updates that are relevant to investors and industry observers.
Recent news has featured Aptar Pharma’s nasal and ophthalmic platforms, such as LuerVax and Spray Divider being used in a Phase II clinical trial of an intranasal COVID-19 vaccine candidate, and Bidose liquid nasal spray systems delivering an FDA-approved treatment for paroxysmal supraventricular tachycardia. The company also reports on developments in eye care, including its Beat the Blink technology and preservative-free multidose dispensers, as well as broader portfolios of ophthalmic solutions.
Aptar’s Digital Health division appears frequently in updates related to connected health tools and data-driven care. Examples include the integration of the Migraine Buddy app with biometric data from wearable devices and FDA 510(k) clearance for HeroTracker Sense, a connected add-on for metered-dose inhalers within a respiratory disease management platform.
Investors following ATR news will also find earnings releases, segment performance commentary, conference participation announcements and information on capital markets activity, such as senior notes offerings. This news page brings together these items so readers can review Aptar’s latest product milestones, partnerships, digital health initiatives and financial communications in one place.
Aptar (NYSE: ATR) announced its 2026 quarterly conference call schedule with dates and times for earnings-related calls and accompanying press release timing.
Press release dates (after NYSE close) and conference calls (all at 8:00 a.m. CT):
- 4Q & Annual 2025: Press release Feb 5, 2026 — Call Feb 6, 2026
- 1Q 2026: Press release Apr 30, 2026 — Call May 1, 2026
- 2Q 2026: Press release Jul 30, 2026 — Call Jul 31, 2026
- 3Q 2026: Press release Oct 29, 2026 — Call Oct 30, 2026
Calls are ~one hour, held in Central time, available live via webcast at the company investor website with replay access on the Investors page. Any updates will be announced in later releases.
Aptar Digital Health (NYSE:ATR) announced a partnership with ŌURA to integrate Migraine Buddy® with Oura Ring biometric data on January 6, 2026. The integration connects Migraine Buddy’s symptom tracking, reporting, and coaching with continuous Oura metrics including sleep, heart rate variability, temperature trends, and cycle insights.
The joint solution aims to give millions of users—especially women—personalized visibility into migraine patterns and potential triggers to support better self‑management.
Aptar (NYSE:ATR) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. Stephan Tanda, President and CEO, will present at 11:15 a.m. Eastern; Vanessa Kanu, EVP and CFO, and Gael Touya, President Aptar Pharma, will also be available.
A live audio webcast and presentation materials will be accessible in the Investors section of the company website at www.aptar.com.
Aptar (NYSE: ATR) announced its Bidose (BDS) Liquid Nasal Spray System is the delivery mechanism for CARDAMYST (etripamil) nasal spray, which received FDA approval for conversion of acute symptomatic PSVT to sinus rhythm in adults on December 17, 2025.
The product pairs two Bidose devices in a protective dual-container with an integrated cap designed to prevent accidental activation and aid portability. Aptar provided device development and regulatory support via its Pharma Services offerings in collaboration with Milestone Pharmaceuticals.
Aptar (NYSE: ATR) was named one of America’s Most Responsible Companies 2026 by Newsweek for the seventh consecutive year, ranking 56 of 600 U.S. companies. The recognition covers ESG performance across Environment, Social and Governance and used 30+ KPIs plus a 26,000-person perception survey. Aptar highlighted investments in renewable energy, landfill-free site certifications, recyclable/refillable product design, and ongoing sustainability reporting.
Aptar (NYSE: ATR) announced on December 1, 2025 that it has acquired Sommaplast, a Brazil-based supplier of oral dosing pharma packaging including closures, droppers, dispensers and dosing cups.
Sommaplast operates a facility in Sao Paulo with a team of over 400 employees and more than 20 years of history. The acquisition expands Aptar's manufacturing footprint in Brazil alongside facilities in Cajamar, Jundiaí, Maringá and Camaçari and is framed as a move to strengthen presence in Latin America and capture growth in Brazil's oral dosing, OTC and nutraceutical markets.
Aptar (NYSE: ATR) announced it will present at the Jefferies Global Healthcare Conference on Wednesday, November 19, 2025. Stephan Tanda, President and CEO, will present at 7:00 a.m. Eastern Standard Time, with Vanessa Kanu, Executive Vice President and CFO, and Gael Touya, President Aptar Pharma, also available. A live audio webcast and presentation materials will be accessible in the Investors section of the company's website at www.aptar.com.
Summary not available.
Aptar Digital Health (ATR) announced that the U.S. FDA granted 510(k) clearance on October 16, 2025 for HeroTracker® Sense, a Bluetooth-enabled Class II connected add-on sensor for pressurized metered-dose inhalers (pMDIs).
HeroTracker Sense is designed for users aged 12 and above, is compatible with commonly prescribed asthma and COPD inhalers including Ventolin HFA and Advair, and integrates with Aptar's Respiratory Disease Management Platform to provide real-time usage tracking, reminders, inhaler technique feedback, and educational resources via a mobile app.
Aptar (NYSE: ATR) was named one of the World’s Top Companies for Women 2025 by Forbes and Statista, marking the company’s fifth consecutive year on the list. Aptar is ranked 72 of 400 companies evaluated from an anonymous survey of over 120,000 women in 36 countries. The ranking is based on employer brand, public opinion and leadership score from surveys conducted over a two-year period.